Industry News

Acadia Pharma’s (ACAD) Nuplazid Approved by FDA For Hallucinations and Delusions Associated with Parkinson’s

“We are grateful to the many patients and investigators who participated in NUPLAZID's
studies. NUPLAZID represents the culmination of many … NUPLAZID will be available through a specialty
network. Patients and physicians can access …

Read the source article at

Note: The information provided here is for reference use only and does not constitute the rendering of legal or other professional advice by McKesson. Readers should consult appropriate professionals for advice and assistance prior to making important decisions regarding their business. McKesson is not advocating any particular program or approach herein. McKesson is not responsible for, nor will it bear any liability for the content provided herein.